Changes to Health Technology Assessment (HTA) in Europe offer new opportunities to streamline processes and get innovative ...

BridgeBio Pharma has dosed the first subject in the ACT-EARLY study of acoramidis, a drug intended to prevent transthyretin ...

How important is it to understand the natural history of disease before embarking on drug development ... need can also help direct the development process. Understanding the disease for which ...

Discover how scientists imaged the Parkinson’s protein PINK1, unlocking insight into its role in mitochondrial quality ...

Liquid biopsies offer a less invasive, yet highly informative, alternative to traditional diagnostic methods. This article ...

First Quarter 2025 Financial and Operating Results: ...

Q1 2025 revenue of $17.3 million, with product sales of $14.0 million, representing 76% growth over Q1 2024 and the 17th ...

Atea defines working capital as current assets less current liabilities. See the Company's condensed consolidated financial ...

Lantern Pharma Inc. ( NASDAQ: LTRN) Q1 2025 Earnings Conference Call May 15, 2025 9:00 AM ET Panna Sharma - President & CEO David Margrave - CFO ...

Slow progress, pipeline uncertainty & lack of catalysts weigh despite strong cash. Click to read why KYMR stock is a Hold.